Celldex Therapeutics (CLDX) has caught investor attention after presenting fresh Phase 2 and open label extension data for barzolvolimab in multiple urticaria indications at the AAAAI 2026 meeting in Philadelphia.

The latest barzolvolimab readouts arrive after a busy few weeks for Celldex, including multiple AAAAI presentations, completion of enrollment in the global Phase 3 CSU program and full year 2025 results that showed revenue of US$1.55 million alongside a net loss of US$258.76 million. At a share price of US$29.43, the stock has a 30 day share price return of 23.86% and a 1 year total shareholder return of 42.38%, which hints at building momentum despite a weaker 3 year total shareholder return of 29.59%.

If this barzolvolimab news has you looking more broadly at allergy and immunology trends, it could be a good moment to scan 32 healthcare AI stocks for other potential ideas in the space.

With barzolvolimab data keeping excitement high but Celldex still posting a US$258.76 million annual loss, investors may need to consider whether CLDX remains underappreciated by the market or is already pricing in years of future growth.

Preferred Price to Book of 3.7x: Is it justified?

Celldex is trading on a P/B of 3.7x, which sits between peers and the wider comparison group, so the current share price reflects a mixed valuation signal.

P/B compares the market value of the company to its book value. This measure is often used for early stage or unprofitable biotechs where earnings and sales do not yet tell the full story. For Celldex, this lens matters because the business is still loss making, has revenue of just $1.55 million, and investors are mostly focused on assets such as the barzolvolimab program rather than current income.

On one side, Celldex is described as good value versus a broader peer average P/B of 14.7x, which suggests the market is not assigning the kind of premium some other antibody and mast cell focused names receive. On the other, the same P/B of 3.7x is labelled expensive against the US Biotechs industry average of 2.7x, which implies investors are already paying up relative to the sector and could be factoring in expectations that extend well beyond today’s $1.55 million in revenue and current losses.

That split view highlights the tension between upside implied by specialist comparisons and the richer pricing versus the wider biotech industry. It also provides a reference point for judging whether future clinical and revenue milestones would justify the market moving closer to either benchmark.

Result: Price-to-book of 3.7x (ABOUT RIGHT)

However, that story can change quickly if key barzolvolimab studies disappoint or if Celldex needs to raise fresh capital while still reporting heavy losses.

Another View: What Our DCF Model Is Signalling

Price to book suggests CLDX is roughly in the middle of the pack, but our DCF model presents a different perspective. With the shares at $29.43 and our future cash flow value estimate at $96.93, the model indicates a large gap. The question is whether those implied cash flows seem realistic to you.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celldex Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mixed signals across valuation, clinical progress and recent returns, do you feel the balance tips more toward risk or reward for Celldex right now? Take a moment to look through the data yourself, weigh the trade off between its concerns and potential, and then check out 2 key rewards and 2 important warning signs to see how those risks and rewards stack up in one place.

Looking for more investment ideas?

If CLDX has sharpened your focus, do not stop here. Broader context from other ideas can sharpen your judgment and highlight opportunities you might otherwise miss.

• Target reliable compounding by scanning our list of 16 dividend fortresses that may suit investors who want income without ignoring quality.
• Hunt for mispriced potential with the screener containing 24 high quality undiscovered gems and spot companies the market might not be paying full attention to yet.
• Dial down portfolio risk by reviewing 63 resilient stocks with low risk scores and see which companies line up with a more cautious approach to capital.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.